dysport 500unit powder for solution for injection vials
ipsen ltd - botulinum toxin type a - powder for solution for injection - 500unit
decapeptyl sr 11.25mg powder and solvent for suspension for injection vials
ipsen ltd - triptorelin - powder and solvent for suspension for injection - 11.25mg
decapeptyl sr 22.5mg powder and solvent for suspension for injection vials
ipsen ltd - triptorelin embonate - powder and solvent for suspension for injection - 22.5mg
dysport 300unit powder for solution for injection vials
ipsen ltd - botulinum toxin type a - powder for solution for injection - 300unit
somatuline autogel 60mg/0.5ml solution for injection pre-filled syringes with safety system
ipsen ltd - lanreotide acetate - solution for injection - 120mg/1ml
somatuline autogel 90mg/0.5ml solution for injection pre-filled syringes with safety system
ipsen ltd - lanreotide acetate - solution for injection - 180mg/1ml
somatuline autogel 120mg/0.5ml solution for injection pre-filled syringes with safety system
ipsen ltd - lanreotide acetate - solution for injection - 240mg/1ml
salvacyl 11.25mg powder and solvent for suspension for injection vials
ipsen ltd - triptorelin - powder and solvent for suspension for injection - 11.25mg
azzalure, 125 speywood units, powder for solution for injection
ipsen pharma - clostridium botulinum toxin type a haemagglutinin complex - powder for solution for injection - 125 speywood - other muscle relaxants, peripherally acting agents; botulinum toxin
somatuline autogel (lanreotide as acetate) 120mg solution for injection prefilled syringe
ipsen pty ltd - lanreotide acetate, quantity: 149.4 mg (equivalent: lanreotide, qty 125.5 mg) - injection, solution - excipient ingredients: glacial acetic acid; water for injections - somatuline autogel is indicated for: - the treatment of acromegaly when the circulating levels of growth hormone and igf-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory -the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours -the treatment of gastroenteropancreatic neuroendocrine tumours (gep-nets) in adult patients with unresectable locally advanced or metastatic disease.